The Accuracy and Reliability of Sleep Staging and Sleep Biomarkers in Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder

Daniel J Levendowski,Thomas C Neylan,Joyce K Lee-Iannotti,Paul C Timm,Cyrus Guevarra,Elise Angel,David Shprecher,Gandis Mazeika,Christine M Walsh,Bradley F Boeve,Erik K St Louis

DOI: https://doi.org/10.2147/NSS.S396853

2023-05-03

Nature and Science of Sleep

Abstract:Daniel J Levendowski, 1 Thomas C Neylan, 2 Joyce K Lee-Iannotti, 3 Paul C Timm, 4 Cyrus Guevarra, 3 Elise Angel, 1 David Shprecher, 5 Gandis Mazeika, 1 Christine M Walsh, 6 Bradley F Boeve, 4 Erik K St Louis 4 1 Sleep and Respiratory Research, Advanced Brain Monitoring, Inc, Carlsbad, CA, USA; 2 Weill Institute for Neurosciences, University of California, San Francisco, CA, USA; 3 Department of Neurology and Medicine, Banner University Medical Center, Phoenix, AZ, USA; 4 Mayo Center for Sleep Medicine, Departments of Neurology and Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, USA; 5 Banner Sun Health Research Institute, Sun City, AZ, USA; 6 Memory and Aging Center, University of California, San Francisco, CA, USA Correspondence: Daniel J Levendowski, Advanced Brain Monitoring, Inc, 2237 Faraday Avenue, Carlsbad, CA, 92008, USA, Tel +1 760 521 1545, Fax +1 760 476 3620, Email Purpose: This study aimed to establish the diagnostic accuracy of a previously validated sleep staging system in patients with probable isolated REM sleep behavior disorder (iRBD), and to compare physicians' diagnoses of iRBD based on REM sleep without atonia (RSWA) to non-REM hypertonia (NRH), a sleep measure independently associated with Parkinsonian spectrum disorders. Patients and Methods: Twenty-six patients with a history of dream enactment behavior underwent a diagnostic PSG with simultaneous Sleep Profiler (SP) acquisition at two sites. PSG and SP records were sleep staged, and two sleep neurologists independently diagnosed iRBD based on the presence or absence of polysomnographic identified RSWA. Comparisons for PSG vs SP sleep staging and the qualitative presence or absence of PSG-based RSWA vs automated SP-detected NRH was performed using kappa coefficients ( k ), positive and negative percent agreements (PPA and NPA), and chi-square tests. Results: The kappa scores from Sites-1 and − 2 for PSG vs SP staging were different for Wake ( k =0.82 vs 0.65), N2 ( k =0.63 vs 0.72) and REM ( k =0.83 vs.0.72). The by-site kappa values for stage N3 increased from 0.72 and 0.37 to 0.88 and 0.74 after PSG records were reedited. The kappa values for between-physician agreement in iRBD diagnoses were fair (k = 0.22). The agreement between each physician's iRBD diagnoses and NRH were also fair ( k =0.29 and 0.22). Abnormal NRH agreed with at least one physician's iRBD diagnosis in 83% of the records. The PPA resulting from between-physician iRBD agreement was stronger and the NPA weaker than the values obtained from comparison of each physician's iRBD diagnosis and abnormal NRH. Conclusion: The potential utility of RSWA and stage N3 as neurodegenerative disorder biomarkers was influenced by between-site variability in visual scoring. The degree to which NRH was associated with iRBD was similar to the between-physician agreement in their diagnosis of iRBD using RSWA. Keywords: RBD, sleep biomarker, sleep staging, accuracy, non-REM hypertonia Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) is a parasomnia recognized as a prodromal biomarker for alpha-synuclein pathologies, including Parkinson disease, dementia with Lewy bodies, and multiple system atrophy. 1,2 iRBD has also been variably associated with progressive supranuclear palsy, a tauopathy. Dream enactment behaviors, characterized by complex vocal or motor behaviors during REM sleep, are the primary iRBD symptom that leads to its recognition. iRBD-related dream enactment ranges from subtle hand gestures to violent punching and kicking that may lead to self or bed partner injury. 1–4 Within a 10- to 15-year period after diagnosis of iRBD, approximately 70–75% of patients develop a defined neurodegenerative disease. 1,4 Between 40% and 50% of patients with Parkinson's disease also have RBD, particularly those who are older with a longer disease duration, and who exhibit greater disease severity and/or more severe motor fluctuations. 5 Despite the injury potential and neurodegenerative consequences, many iRBD patients are unaware of their dream enactment symptoms, 6 leading to delayed diagnosis. Over 1% of the adult community population has iRBD with the prevalence increasing with age. 7 The ratio iRBD is 9 to 1 in men versus women; 8 however, IRBD is likely underdiagnosed in women, possibly a result of more subtle and less violent dream enactment behaviors. 9,10 It is common for clinicians to overlook the relatively frequent occurrence of REM sleep without atonia (RSWA) without clin -Abstract Truncated-

neurosciences,clinical neurology